Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.

Rubin RR, Peyrot M

Current medical research and opinion1 Aug 2007Cited by 12 (Europe PMC)

PMID17624233DOI10.1185/030079907x210804PepBankPUB-17624233

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 1 or type 2 diabetes, satisfaction with glucose control was higher with pramlintide-containing regimens than pre-study regimens.
In plain wordsIn patients with diabetes, satisfaction with glucose control was higher with the pramlintide regimen than the previous insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction with glucose control
Study
n: not reported in source
Comparator
Pre-study insulin regimens
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Participants rated the study treatment regimen including pramlintide significantly (p < 0.001) superior to their pre-study regimens in terms of 'glucose control', 'eating-weight control', and 'general benefits' at all three TSQ administrations.
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
Report a problemFND-1762423301
02HumanNon-randomized trialEfficacy outcome
In patients with type 1 or type 2 diabetes, satisfaction with eating-weight control was higher with pramlintide-containing regimens than pre-study regimens.
In plain wordsIn patients with diabetes, satisfaction with eating and weight control was higher with the pramlintide regimen than the previous regimen.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction with eating-weight control
Study
n: not reported in source
Comparator
Pre-study insulin regimens
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Participants rated the study treatment regimen including pramlintide significantly (p < 0.001) superior to their pre-study regimens in terms of 'glucose control', 'eating-weight control', and 'general benefits' at all three TSQ administrations.
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
Report a problemFND-1762423302
03HumanNon-randomized trialEfficacy outcome
In patients with type 1 or type 2 diabetes, satisfaction with general benefits was higher with pramlintide-containing regimens than pre-study regimens.
In plain wordsIn patients with diabetes, satisfaction with general benefits was higher with the pramlintide regimen than the previous regimen.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction with general benefits
Study
n: not reported in source
Comparator
Pre-study insulin regimens
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Participants rated the study treatment regimen including pramlintide significantly (p < 0.001) superior to their pre-study regimens in terms of 'glucose control', 'eating-weight control', and 'general benefits' at all three TSQ administrations.
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
Report a problemFND-1762423303
04HumanObservational studyOther
In patients with diabetes, reaching the maximum protocol pramlintide dose was associated with higher glucose-control and general-benefit satisfaction.
In plain wordsIn patients with diabetes, those reaching the maximum pramlintide dose reported greater glucose-control and general-benefit satisfaction than those who did not.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction association with maximum pramlintide dose
Study
n: not reported in source
Comparator
Participants unable to reach maximum protocol dose
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Participants who were able to reach the maximum dosage of pramlintide per protocol, and those who experienced more reduction in PPG and insulin requirements during the study, reported higher satisfaction with glucose control and general benefits;
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
Report a problemFND-1762423304

Studies that did not test the peptide alone3

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

05HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In pramlintide-treated patients with diabetes, greater postprandial glucose reductions were associated with higher glucose-control and general-benefit satisfaction.
In plain wordsIn patients receiving pramlintide, larger glucose reductions after meals were linked to greater glucose-control and general-benefit satisfaction.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction association with postprandial glucose reduction
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Participants who were able to reach the maximum dosage of pramlintide per protocol, and those who experienced more reduction in PPG and insulin requirements during the study, reported higher satisfaction with glucose control and general benefits;
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1762423305
06HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In pramlintide-treated patients with diabetes, greater insulin requirement reductions were associated with higher glucose-control and general-benefit satisfaction.
In plain wordsIn patients receiving pramlintide, larger insulin requirement reductions were linked to greater glucose-control and general-benefit satisfaction.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction association with insulin requirement reduction
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Participants who were able to reach the maximum dosage of pramlintide per protocol, and those who experienced more reduction in PPG and insulin requirements during the study, reported higher satisfaction with glucose control and general benefits;
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1762423306
07HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In pramlintide-treated patients with diabetes, greater weight loss was associated with higher satisfaction on all three treatment satisfaction measurements.
In plain wordsIn patients receiving pramlintide, greater weight loss was linked to higher satisfaction on all three treatment satisfaction measurements.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatisfaction association with weight loss
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
those who lost more weight reported higher treatment satisfaction on all three TSQ measurements.
3 context sentences(design, population, supporting numbers)
Summary · context
In this open-label study 240 participants with type 1 diabetes and 160 participants with type 2 diabetes added pramlintide to their established insulin regimen.
Summary · context
Mealtime insulin doses were subsequently adjusted to optimize glycemic control.
Summary · context
Participants completed a treatment satisfaction questionnaire (TSQ) at months 1, 3, and 6.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1762423307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.